Bio-Rad Q4 revenue flat YoY; non-GAAP EPS $3.31, guides FY2023 ~6-7% growth

BIO-RAD LABORATORIES, INC.

2022-FY EPS reported -$121.79 revenue$2,802,200,000

Q4 net sales $730.3M, -0.3% reported; currency-neutral +5.8% (+10.6% ex-COVID).
Life Science segment $359.7M (+10.1%); Clinical Diagnostics $369.6M (-8.7%).
GAAP net income $827.7M ($27.78 diluted) from Sartorius fair value; non-GAAP net income $98.5M ($3.31).
Full-year 2022 net sales $2,802.2M (-4.1%); non-GAAP EPS $14.42 vs $15.94 prior year.
FY2023 outlook: non-GAAP currency-neutral revenue growth ~6-7%, non-GAAP operating margin ~19.5%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

BIO-RAD LABORATORIES, INC. reported Fourth-quarter 2022 results: revenue $730.3 million, net income $827.7 million, EPS $27.78 per share, on a diluted basis.

Period: Fourth-quarter 2022
Revenue: $730.3 million
Net income: $827.7 million
EPS: $27.78 per share, on a diluted basis
Result: reported results

Exact text from the filing

Fourth-quarter 2022 net sales were $730.3 million, a decrease of 0.3 percent compared to $732.8 million reported for the fourth quarter of 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

BIO-RAD LABORATORIES, INC. reported the full year ended December 31, 2022 results: revenue $2,802.2 million.

Period: the full year ended December 31, 2022
Revenue: $2,802.2 million
Result: reported results

Exact text from the filing

On a reported basis, net sales for the full year 2022 decreased 4.1 percent to $2,802.2 million compared to $2,922.5 million for the prior year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIO-RAD LABORATORIES, INC. reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BIO-RAD LABORATORIES, INC. filing history →

Source: SEC EDGAR

accession 0000012208-23-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.